Compare COCH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COCH | SCYX |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 42.4M |
| IPO Year | N/A | 2014 |
| Metric | COCH | SCYX |
|---|---|---|
| Price | $0.67 | $3.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | ★ 327.4K | 79.3K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.57 |
| 52 Week High | $1.89 | $5.62 |
| Indicator | COCH | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 45.87 |
| Support Level | $0.64 | $3.68 |
| Resistance Level | $0.74 | $5.10 |
| Average True Range (ATR) | 0.06 | 0.37 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 10.90 | 15.29 |
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.